Role and Therapeutic Potential of Melatonin in Various Type of Cancers

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li HB. Dietary natural products for prevention and treatment of liver cancer. Nutrients. 2016;8(3):156. doi:10.3390/nu8030156
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi:10.1016/s0092-8674(00)81683-9
   PubMed Web of Science ®Google Scholar
• Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2(5):331–341. doi:10.1038/nrc795
   PubMed Web of Science ®Google Scholar
• Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3(12):895–902. doi:10.1038/nrc1232
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602. doi:10.1038/nature07586
   PubMed Web of Science ®Google Scholar
• Waldum HL, Sandvik AK, Brenna E, Fossmark R, Qvigstad G, Soga J. Classification of tumours. J Exp Clin Cancer Res. 2008;27(1):70. doi:10.1186/1756-9966-27-70
   PubMedGoogle Scholar
• Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1):e12370. doi:10.1111/jpi.12370
   Web of Science ®Google Scholar
• Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017;18(4):843. doi:10.3390/ijms18040843
   PubMed Web of Science ®Google Scholar
• Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016;24(3):1097–1105. doi:10.1007/s00520-015-2883-6
   PubMed Web of Science ®Google Scholar
• Acuña-Castroviejo D, Rahim I, Acuña-Fernández C, et al. Melatonin, clock genes and mitochondria in sepsis. Cell Mol Life Sci. 2017;74(21):3965–3987. doi:10.1007/s00018-017-2610-1
   PubMed Web of Science ®Google Scholar
• Zhao M, Wan J, Zeng K, et al. The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: a retrospective study. J Cancer. 2016;7(7):831–836. doi:10.7150/jca.14573
   PubMed Web of Science ®Google Scholar
• Vijayalaxmi V, Thomas CR, Reiter RJ, Herman,TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20(10):2575–2601. doi:10.1200/jco.2002.11.004
   PubMed Web of Science ®Google Scholar
• Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function. FASEB j. 2010;24(10):3603–3624. doi:10.1096/fj.10-154450
   PubMed Web of Science ®Google Scholar
• Cutando A, López-Valverde A, Arias-Santiago S, et al. Role of melatonin in cancer treatment. Anticancer Res. 2012;32(7):2747–2753.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7(3):189–203. doi:10.1177/1534735408322846
   PubMed Web of Science ®Google Scholar
• Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003;60(7):1407–1426. doi:10.1007/s00018-003-2319-1
   PubMed Web of Science ®Google Scholar
• Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015;22(3):R183–R204. doi:10.1530/ERC-15-0030
   PubMed Web of Science ®Google Scholar
• Khoory R, Stemme D. Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res. 1988;5(3):251–258. doi:10.1111/j.1600-079x.1988.tb00651.x
   PubMed Web of Science ®Google Scholar
• Bartsch H, Buchberger A, Franz H, et al. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci. 2000;67(24):2953–2960. doi:10.1016/s0024-3205(00)00882-1
   PubMed Web of Science ®Google Scholar
• Karasek M, Fraschini F. Is there a role for the pineal gland in neoplastic growth?. In: Fraschini F, Reiter RJ, editors. Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. Boston, MA:Springer; 1991:243–251.
   Google Scholar
• Nooshinfar E, Safaroghli-Azar A, Bashash D, Akbari ME. Melatonin, an inhibitory agent in breast cancer. Breast Cancer. 2017;24(1):42–51. doi:10.1007/s12282-016-0690-7
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896–39921. doi:10.18632/oncotarget.16379
   PubMedGoogle Scholar
• Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol. 1989;25(5):789–795. doi:10.1016/0277-5379(89)90122-3
   PubMedGoogle Scholar
• Lissoni P, Barni S, Tancini G, et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology. 1993;50(6):399–402. doi:10.1159/000227218
   PubMed Web of Science ®Google Scholar
• Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5(2):126–129. doi:10.1007/bf01262569
   PubMed Web of Science ®Google Scholar
• Lissoni P, Rovelli F, Brivio F, Brivio O, Fumagalli L. Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat Immun. 1998;16(1):1–5. doi:10.1159/000069464
   PubMedGoogle Scholar
• Lissoni P, Rovelli F, Giani L, et al. Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease. Int J Biol Markers. 1998;13(3):154–157. doi:10.1177/172460089801300306
   PubMed Web of Science ®Google Scholar
• Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro Endocrinol Lett. 2003;24(1–2):83–85.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35(1):12–15. doi:10.1034/j.1600-079x.2003.00032.x
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Alimova IN, Baturin DA, et al. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer. 2003;103(3):300–305. doi:10.1002/ijc.10827
   PubMed Web of Science ®Google Scholar
• Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol. 2007;55(3–4):201–204. doi:10.1016/j.patbio.2006.12.025
   PubMedGoogle Scholar
• Lissoni P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol. 2007;55(3–4):198–200. doi:10.1016/j.patbio.2006.12.008
   PubMedGoogle Scholar
• Song N, Kim AJ, Kim HJ, et al. Melatonin suppresses doxorubicin-induced premature senescence of A549 lung cancer cells by ameliorating mitochondrial dysfunction. J Pineal Res. 2012;53(4):335–343. doi:10.1111/j.1600-079X.2012.01003.x
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gui S, Zhou Q, Wang Y. Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoS One. 2014;9(7):e101132. doi:10.1371/journal.pone.0101132
   PubMed Web of Science ®Google Scholar
• Plaimee P, Weerapreeyakul N, Barusrux S, Johns NP. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif. 2015;48(1):67–77. doi:10.1111/cpr.12158
   PubMed Web of Science ®Google Scholar
• Chao CC, Chen PC, Chiou PC, et al. Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist. Clin Sci. 2019;133(5):709–722. doi:10.1042/cs20180945
   Web of Science ®Google Scholar
• Jablonska K, Nowinska K, Piotrowska A, et al. Prognostic impact of melatonin receptors MT1 and MT2 in non-small cell lung cancer (NSCLC). Cancers. 2019;11(7):1001. doi:10.3390/cancers11071001
   PubMed Web of Science ®Google Scholar
• Ma Z, Liu D, Di S, et al. Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. J Pineal Res. 2019;67(2):e12587. doi:10.1111/jpi.12587
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Jeyaraj M, Kang MH, Kim JH. Melatonin enhances palladium-nanoparticle-induced cytotoxicity and apoptosis in human lung epithelial adenocarcinoma cells A549 and H1229. Antioxidants (Basel). 2020;9(4). doi:10.3390/antiox9040357
   PubMedGoogle Scholar
• Alvarez-Artime A, Cernuda-Cernuda R, Francisco Artime N, et al. Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. Int J Mol Sci. 2020;21(2):548. doi:10.3390/ijms21020548
   PubMed Web of Science ®Google Scholar
• Pourhanifeh MH, Sharifi M, Reiter RJ, Davoodabadi A, Asemi Z. Melatonin and non-small cell lung cancer: new insights into signaling pathways. Cancer Cell Int. 2019;19:131. doi:10.1186/s12935-019-0853-7
   PubMed Web of Science ®Google Scholar
• Kahkesh MH, Salehi Z, Najafi M, Ghobadi A, Izad M, Shirazi A. The inhibitory effect of melatonin on the proliferation of irradiated A549 cell line. J Cancer Res Ther. 2020;16(6):1500–1505. doi:10.4103/jcrt.JCRT_682_19
   PubMed Web of Science ®Google Scholar
• Liu PI, Chang AC, Lai JL, et al. Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases. Oncogene. 2021;40:1503–1515. doi:10.1038/s41388-020-01613-4
   PubMed Web of Science ®Google Scholar
• Lissoni P, Tancini G, Barni S, et al. Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients. Tumori Journal. 1988;74(3):339–345. doi:10.1177/030089168807400317
   PubMed Web of Science ®Google Scholar
• Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm. 1981;52(4):281–294. doi:10.1007/bf01256753
   PubMed Web of Science ®Google Scholar
• Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 1982;216(4549):1003–1005. doi:10.1126/science.7079745
   PubMed Web of Science ®Google Scholar
• Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl. 1986;21:433–449.
   PubMedGoogle Scholar
• Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988;48(21):6121–6126.
   PubMed Web of Science ®Google Scholar
• Crespo D, Fernández-Viadero C, Verduga R, Ovejero V, Cos S. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res. 1994;16(4):215–222. doi:10.1111/j.1600-079x.1994.tb00105.x
   PubMed Web of Science ®Google Scholar
• Lemus-Wilson A, Kelly PA, Blask DE. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer. 1995;72(6):1435–1440. doi:10.1038/bjc.1995.526
   PubMed Web of Science ®Google Scholar
• Eck KM, Yuan L, Duffy L, et al. A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells. Br J Cancer. 1998;77(12):2129–2137. doi:10.1038/bjc.1998.357
   PubMed Web of Science ®Google Scholar
• Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58(19):4383–4390.
   PubMed Web of Science ®Google Scholar
• Cini G, Neri B, Pacini A, et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. J Pineal Res. 2005;39(1):12–20. doi:10.1111/j.1600-079X.2004.00206.x
   PubMed Web of Science ®Google Scholar
• Cos S, Blask DE, Lemus-Wilson A, Hill AB. Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of MCF-7 human breast cancer cells in culture. J Pineal Res. 1991;10(1):36–42. doi:10.1111/j.1600-079x.1991.tb00007.x
   PubMed Web of Science ®Google Scholar
• Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65(4):415–420. doi:10.1016/s0024-3205(99)00262-3
   PubMed Web of Science ®Google Scholar
• Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192(1–2):147–156. doi:10.1016/s0303-7207(02)00029-1
   PubMed Web of Science ®Google Scholar
• Cucina A, Proietti S, D’Anselmi F, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res. 2009;46(2):172–180. doi:10.1111/j.1600-079X.2008.00645.x
   PubMed Web of Science ®Google Scholar
• Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS, Park YS. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res. 2011;51(3):345–352. doi:10.1111/j.1600-079X.2011.00896.x
   PubMed Web of Science ®Google Scholar
• Margheri M, Pacini N, Tani A, et al. Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. Eur J Pharmacol. 2012;681(1–3):34–43. doi:10.1016/j.ejphar.2012.02.011
   PubMed Web of Science ®Google Scholar
• Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res. 2013;54(4):373–380. doi:10.1111/jpi.12007
   PubMed Web of Science ®Google Scholar
• Gonçalves Ndo N, Colombo J, Lopes JR, et al. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PLoS One. 2016;11(3):e0150407. doi:10.1371/journal.pone.0150407
   PubMed Web of Science ®Google Scholar
• Jardim-Perassi BV, Lourenço MR, Doho GM, et al. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anticancer Agents Med Chem. 2016;16(3):347–358. doi:10.2174/1871520615666150511094201
   PubMed Web of Science ®Google Scholar
• Wang T, Liu B, Guan Y, et al. Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways. Thorac Cancer. 2018;9(3):368–375. doi:10.1111/1759-7714.12587
   PubMed Web of Science ®Google Scholar
• Proietti S, Catizone A, Masiello MG, et al. Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation. J Pineal Res. 2018;64(4):e12467. doi:10.1111/jpi.12467
   PubMed Web of Science ®Google Scholar
• Colombo J, Jardim-Perassi BV, Ferreira JPS, et al. Melatonin differentially modulates NF-кB expression in breast and liver cancer cells. Anticancer Agents Med Chem. 2018;18(12):1688–1694. doi:10.2174/1871520618666180131112304
   PubMed Web of Science ®Google Scholar
• Lacerda JZ, Ferreira LC, Lopes BC, et al. Therapeutic potential of melatonin in the regulation of miR-148a-3p and angiogenic factors in breast cancer. Microrna. 2019;8(3):237–247. doi:10.2174/2211536608666190219095426
   PubMedGoogle Scholar
• Gulbahce-Mutlu E, Baltaci SB, Menevse E, Mogulkoc R, Baltaci AK. The effect of zinc and melatonin administration on lipid peroxidation, IL-6 levels, and element metabolism in DMBA-induced breast cancer in rats. Biol Trace Elem Res. 2020;199(3):1044–1051. doi:10.1007/s12011-020-02238-0
   PubMed Web of Science ®Google Scholar
• Palmer ACS, Zortea M, Souza A, et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: a randomized, double-blind, placebo-controlled trial. PLoS One. 2020;15(4):e0231379. doi:10.1371/journal.pone.0231379
   PubMed Web of Science ®Google Scholar
• Lin PH, Tung YT, Chen HY, et al. Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. J Pineal Res. 2020;68(1):e12620. doi:10.1111/jpi.12620
   PubMed Web of Science ®Google Scholar
• Talib WH. A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. Nutrition. 2020;72:110659. doi:10.1016/j.nut.2019.110659
   PubMed Web of Science ®Google Scholar
• Pourhanifeh MH, Mehrzadi S, Hosseinzadeh A. Melatonin and regulation of miRNAs: novel targeted therapy for cancerous and noncancerous disease. Epigenomics. 2021;13(1):65–81. doi:10.2217/epi-2020-0241
   PubMed Web of Science ®Google Scholar
• Hadadi E, Acloque H. Role of circadian rhythm disorders in EMT and tumor-immune interactions in endocrine-related cancers. Endocr Relat Cancer. 2021;28:R67–R80. doi:10.1530/erc-20-0390
   PubMed Web of Science ®Google Scholar
• Jardin I, Diez-Bello R, Falcon D, et al. Melatonin downregulates TRPC6, impairing store-operated calcium entry in triple negative breast cancer cells. J Biol Chem. 2020. doi:10.1074/jbc.RA120.015769
   Web of Science ®Google Scholar
• Jin Y, Choi YJ, Heo K, Park SJ. Melatonin as an oncostatic molecule based on its anti-aromatase role in breast cancer. Int J Mol Sci. 2021;22(1):438. doi:10.3390/ijms22010438
   PubMed Web of Science ®Google Scholar
• Ahabrach H, El Mlili N, Errami M, Cauli O. Circadian rhythm and concentration of melatonin in breast cancer patients. Endocr Metab Immune Disord Drug Targets. 2020;20. doi:10.2174/1871530320666201201110807
   Google Scholar
• Chuffa LGA, Lupi LA, Cucielo MS, Silveira HS, Reiter RJ, Seiva FRF. Melatonin promotes uterine and placental health: potential molecular mechanisms. Int J Mol Sci. 2019;21(1). doi:10.3390/ijms21010300
   PubMed Web of Science ®Google Scholar
• Kwon YJ, Seo EB, Kwon SH, et al. Extracellular acidosis promotes metastatic potency via decrease of the BMAL1 circadian clock gene in breast cancer. Cells. 2020;9(4):989. doi:10.3390/cells9040989
   PubMed Web of Science ®Google Scholar
• Maroufi NF, Vahedian V, Hemati S, et al. Targeting cancer stem cells by melatonin: effective therapy for cancer treatment. Pathol Res Pract. 2020;216(5):152919. doi:10.1016/j.prp.2020.152919
   PubMed Web of Science ®Google Scholar
• Menéndez-Menéndez J, Hermida-Prado F, Granda-Díaz R, et al. Deciphering the molecular basis of melatonin protective effects on breast cells treated with Doxorubicin: TWIST1 a transcription factor involved in EMT and metastasis, a novel target of melatonin. Cancers (Basel). 2019;11(7):1011. doi:10.3390/cancers11071011
   PubMed Web of Science ®Google Scholar
• Goyal R, Gupta T, Bal A, Sahni D, Singh G. Role of melatonin in breast carcinoma: correlation of expression patterns of melatonin-1 receptor with estrogen, progesterone, and HER2 receptors. Appl Immunohistochem Mol Morphol. 2020;28(7):518–523. doi:10.1097/pai.0000000000000788
   PubMedGoogle Scholar
• Xiang S, Dauchy RT, Hoffman AE, et al. Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer. J Pineal Res. 2019;67(2):e12586. doi:10.1111/jpi.12586
   PubMed Web of Science ®Google Scholar
• Menéndez-Menéndez J, Martínez-Campa C. Melatonin: an anti-tumor agent in hormone-dependent cancers. Int J Endocrinol. 2018;2018:3271948. doi:10.1155/2018/3271948
   PubMed Web of Science ®Google Scholar
• El-Sokkary GH, Ismail IA, Saber SH. Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway. J Cell Biochem. 2019;120(3):3945–3957. doi:10.1002/jcb.27678
   PubMed Web of Science ®Google Scholar
• Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–874. doi:10.1016/j.eururo.2016.05.043
   PubMed Web of Science ®Google Scholar
• Bray F, Kiemeney LA. Epidemiology of prostate cancer in Europe: patterns, trends and determinants. In: Management of Prostate Cancer. Cham:Springer; 2017:1–27.
   Google Scholar
• Sigurdardottir LG, Markt SC, Rider JR, et al. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur Urol. 2015;67(2):191–194. doi:10.1016/j.eururo.2014.07.008
   PubMed Web of Science ®Google Scholar
• Tai SY, Huang SP, Bao BY, Wu MT. Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: a case-control study. Sci Rep. 2016;6:29606. doi:10.1038/srep29606
   PubMed Web of Science ®Google Scholar
• Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005;63(1):29–43. doi:10.1002/pros.20155
   PubMed Web of Science ®Google Scholar
• Laudon M, Gilad E, Matzkin H, Braf Z, Zisapel N. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab. 1996;81(4):1336–1342. doi:10.1210/jcem.81.4.8636329
   PubMed Web of Science ®Google Scholar
• Gilad E, Laudon M, Matzkin H, et al. Functional melatonin receptors in human prostate epithelial cells. Endocrinology. 1996;137(4):1412–1417. doi:10.1210/endo.137.4.8625918
   PubMed Web of Science ®Google Scholar
• Rimler A, Culig Z, Levy-Rimler G, et al. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate. 2001;49(2):145–154. doi:10.1002/pros.1129
   PubMed Web of Science ®Google Scholar
• Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003;35(3):177–182. doi:10.1034/j.1600-079x.2003.00074.x
   PubMed Web of Science ®Google Scholar
• Paroni R, Terraneo L, Bonomini F, et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res. 2014;57(1):43–52. doi:10.1111/jpi.12142
   PubMed Web of Science ®Google Scholar
• Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res. 2000;29(3):172–183. doi:10.1034/j.1600-079x.2000.d01-64.x
   PubMed Web of Science ®Google Scholar
• Lupowitz Z, Rimler A, Zisapel N. Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin. Cell Mol Life Sci. 2001;58(14):2129–2135. doi:10.1007/pl00000842
   PubMed Web of Science ®Google Scholar
• Tam CW, Mo CW, Yao KM, Shiu SY. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res. 2007;42(2):191–202. doi:10.1111/j.1600-079X.2006.00406.x
   PubMed Web of Science ®Google Scholar
• Shiu SY, Leung WY, Tam CW, Liu VW, Yao KM. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy. J Pineal Res. 2013;54(1):69–79. doi:10.1111/j.1600-079X.2012.01026.x
   PubMed Web of Science ®Google Scholar
• Nah SS, Won HJ, Park HJ, et al. Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. J Pineal Res. 2009;47(1):70–74. doi:10.1111/j.1600-079X.2009.00689.x
   PubMed Web of Science ®Google Scholar
• Tamarindo GH, Ribeiro DL, Gobbo MG, et al. Melatonin and docosahexaenoic acid decrease proliferation of PNT1A prostate benign cells via modulation of mitochondrial bioenergetics and ROS production. Oxid Med Cell Longev. 2019;2019:5080798. doi:10.1155/2019/5080798
   PubMed Web of Science ®Google Scholar
• Wang SW, Tai HC, Tang CH, et al. Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. J Cell Physiol. 2020;236(5):3979–3990. doi:10.1002/jcp.30150
   PubMed Web of Science ®Google Scholar
• Zharinov GM, Bogomolov OA, Chepurnaya IV, Neklasova NY, Anisimov VN. Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Oncotarget. 2020;11(41):3723–3729. doi:10.18632/oncotarget.27757
   PubMedGoogle Scholar
• Calastretti A, Gatti G, Lucini V, et al. Melatonin analogue antiproliferative and cytotoxic effects on human prostate cancer cells. Int J Mol Sci. 2018;19(5):1505. doi:10.3390/ijms19051505
   PubMed Web of Science ®Google Scholar
• Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M, et al. Melatonin decreases glucose metabolism in prostate cancer cells: a (13)C stable isotope-resolved metabolomic study. Int J Mol Sci. 2017;18(8):1620. doi:10.3390/ijms18081620
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912
   PubMed Web of Science ®Google Scholar
• Magalhães B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012;21(1):15–23. doi:10.1097/CEJ.0b013e3283472241
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–532. doi:10.1056/nejm198809013190901
   PubMed Web of Science ®Google Scholar
• Papantoniou K, Castaño-Vinyals G, Espinosa A, et al. Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study. Int J Cancer. 2015;137(5):1147–1157. doi:10.1002/ijc.29400
   PubMed Web of Science ®Google Scholar
• Parent M, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work and the risk of cancer among men. Am J Epidemiol. 2012;176(9):751–759. doi:10.1093/aje/kws318
   PubMed Web of Science ®Google Scholar
• Lin CL, Liu TC, Wang YN, Chung CH, Chien WC. The association between sleep disorders and the risk of colorectal cancer in patients: a population-based nested case-control study. In Vivo. 2019;33(2):573–579. doi:10.21873/invivo.11513
   PubMed Web of Science ®Google Scholar
• Barni S, Lissoni P, Cazzaniga M, et al. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma. Tumori J. 1992;78(6):383–387. doi:10.1177/030089169207800608
   PubMed Web of Science ®Google Scholar
• Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol. 2000;20(1):21–24. doi:10.1002/(sici)1099-1263(200001/02)20:1<21::aid-jat623>3.0.co;2-m
   PubMed Web of Science ®Google Scholar
• Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;22(1):45–47.
   PubMed Web of Science ®Google Scholar
• Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol. 2002;23(5):298–302. doi:10.1159/000068569
   PubMedGoogle Scholar
• Kontek R, Nowicka H. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. Drug Chem Toxicol. 2013;36(3):335–342. doi:10.3109/01480545.2012.737805
   PubMed Web of Science ®Google Scholar
• Wang J, Guo W, Chen W, et al. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res. 2013;54(4):406–416. doi:10.1111/jpi.12035
   PubMed Web of Science ®Google Scholar
• Ji G, Zhou W, Li X, Du J, Li X, Hao H. Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster. Mol Med Rep. 2021;23(3). doi:10.3892/mmr.2021.11826
   Web of Science ®Google Scholar
• León J, Casado J, Jiménez Ruiz SM, et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-κβ. J Pineal Res. 2014;56(4):415–426. doi:10.1111/jpi.12131
   PubMed Web of Science ®Google Scholar
• Hong Y, Won J, Lee Y, et al. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res. 2014;56(3):264–274. doi:10.1111/jpi.12119
   PubMed Web of Science ®Google Scholar
• Wei JY, Li WM, Zhou LL, Lu QN, He W. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J Pineal Res. 2015;58(4):429–438. doi:10.1111/jpi.12226
   PubMed Web of Science ®Google Scholar
• Chovancova B, Hudecova S, Lencesova L, et al. Melatonin-induced changes in cytosolic calcium might be responsible for apoptosis induction in tumour cells. Cell Physiol Biochem. 2017;44(2):763–777. doi:10.1159/000485290
   PubMedGoogle Scholar
• Trivedi PP, Jena GB, Tikoo KB, Kumar V. Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Mol Carcinog. 2016;55(3):255–267. doi:10.1002/mc.22274
   PubMed Web of Science ®Google Scholar
• Bakalova R, Zhelev Z, Shibata S, Nikolova B, Aoki I, Higashi T. Impressive suppression of colon cancer growth by triple combination SN38/EF24/Melatonin: “Oncogenic” versus “Onco-Suppressive” reactive oxygen species. Anticancer Res. 2017;37(10):5449–5458. doi:10.21873/anticanres.11973
   PubMed Web of Science ®Google Scholar
• Liu Z, Zou D, Yang X, et al. Melatonin inhibits colon cancer RKO cell migration by downregulating Rho‑associated protein kinase expression via the p38/MAPK signaling pathway. Mol Med Rep. 2017;16(6):9383–9392. doi:10.3892/mmr.2017.7836
   PubMed Web of Science ®Google Scholar
• Gao Y, Xiao X, Zhang C, et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. J Pineal Res. 2017;62(2):e12380. doi:10.1111/jpi.12380
   Web of Science ®Google Scholar
• Moloudizargari M, Moradkhani F, Hekmatirad S, Fallah M, Asghari MH, Reiter RJ. Therapeutic targets of cancer drugs: modulation by melatonin. Life Sci. 2021;267:118934. doi:10.1016/j.lfs.2020.118934
   PubMed Web of Science ®Google Scholar
• Lee JH, Yoon YM, Han YS, Yun CW, Lee SH. Melatonin promotes apoptosis of oxaliplatin-resistant colorectal cancer cells through inhibition of cellular prion protein. Anticancer Res. 2018;38(4):1993–2000. doi:10.21873/anticanres.12437
   PubMed Web of Science ®Google Scholar
• Lee JH, Yun CW, Han YS, et al. Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regulating cellular prion protein-Oct4 axis. J Pineal Res. 2018;65(4):e12519. doi:10.1111/jpi.12519
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun Z, Du L, et al. Melatonin sensitizes human colorectal cancer cells to γ-ray ionizing radiation in vitro and in vivo. Int J Mol Sci. 2018;19(12):3974. doi:10.3390/ijms19123974
   PubMed Web of Science ®Google Scholar
• Jung JH, Shin EA, Kim JH, et al. NEDD9 inhibition by miR-25-5p activation is critically involved in co-treatment of melatonin- and pterostilbene-induced apoptosis in colorectal cancer cells. Cancers. 2019;11(11):1684. doi:10.3390/cancers11111684
   PubMed Web of Science ®Google Scholar
• Jadid MFS, Aghaei E, Taheri E, et al. Melatonin increases the anticancer potential of doxorubicin in Caco-2 colorectal cancer cells. Environ Toxicol. 2021. doi:10.1002/tox.23105
   Web of Science ®Google Scholar
• Gil-Martín E, López-Muñoz F, Reiter RJ, Romero A. Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy. Future Med Chem. 2020;12(13):1201–1204. doi:10.4155/fmc-2020-0086
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA, Jansen M, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105–113. doi:10.1038/nm.3984
   PubMed Web of Science ®Google Scholar
• Pourhanifeh MH, Mohammadi R, Noruzi S, et al. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int. 2019;19:157. doi:10.1186/s12935-019-0870-6
   PubMed Web of Science ®Google Scholar
• Fu S, Wu H, Zhang H, Lian CG, Lu Q. DNA methylation/hydroxymethylation in melanoma. Oncotarget. 2017;8(44):78163–78173. doi:10.18632/oncotarget.18293
   PubMedGoogle Scholar
• Abdul-Karim RM, Cowey CL. Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Manag Res. 2017;9:433–442. doi:10.2147/cmar.S92546
   PubMed Web of Science ®Google Scholar
• Hernando B, Ibarrola-Villava M, Fernandez LP, et al. Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin. Biol Sex Differ. 2016;7:17. doi:10.1186/s13293-016-0070-1
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956–975. doi:10.1016/j.tranon.2017.09.007
   PubMed Web of Science ®Google Scholar
• Kumar CA, Das UN. Effect of melatonin on two stage skin carcinogenesis in Swiss mice. Med Sci Monit. 2000;6(3):471–475.
   PubMedGoogle Scholar
• Sener G, Jahovic N, Tosun O, Atasoy BM, Yeğen BC. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci. 2003;74(5):563–572. doi:10.1016/j.lfs.2003.05.011
   PubMed Web of Science ®Google Scholar
• Sener G, Paskaloglu K, Toklu H, et al. Melatonin ameliorates chronic renal failure-induced oxidative organ damage in rats. J Pineal Res. 2004;36(4):232–241. doi:10.1111/j.1600-079X.2004.00113.x
   PubMed Web of Science ®Google Scholar
• Vesnushkin GM, Plotnikova NA, Semenchenko AI, Anisimov VN. Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res. 2006;25(4):507–513.
   PubMed Web of Science ®Google Scholar
• Man’cheva TA, Demidov DV, Plotnikova NA, Kharitonova TV, Pashkevich IV, Anisimov VN. Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by benz(a)pyrene in female mice. Bull Exp Biol Med. 2011;151(3):363–365. doi:10.1007/s10517-011-1331-y
   PubMed Web of Science ®Google Scholar
• Kim TK, Lin Z, Tidwell WJ, Li W, Slominski AT. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro. Mol Cell Endocrinol. 2015;404:1–8. doi:10.1016/j.mce.2014.07.024
   PubMed Web of Science ®Google Scholar
• Kleszczyński K, Zwicker S, Tukaj S, et al. Melatonin compensates silencing of heat shock protein 70 and suppresses ultraviolet radiation-induced inflammation in human skin ex vivo and cultured keratinocytes. J Pineal Res. 2015;58(1):117–126. doi:10.1111/jpi.12197
   PubMed Web of Science ®Google Scholar
• Janjetovic Z, Jarrett SG, Lee EF, Duprey C, Reiter RJ, Slominski AT. Melatonin and its metabolites protect human melanocytes against UVB-induced damage: involvement of NRF2-mediated pathways. Sci Rep. 2017;7(1):1274. doi:10.1038/s41598-017-01305-2
   PubMedGoogle Scholar
• Kocyigit A, Guler EM, Karatas E, Caglar H, Bulut H. Dose-dependent proliferative and cytotoxic effects of melatonin on human epidermoid carcinoma and normal skin fibroblast cells. Mutat Res Genet Toxicol Environ Mutagen. 2018;829–830:50–60. doi:10.1016/j.mrgentox.2018.04.002
   PubMed Web of Science ®Google Scholar
• Skobowiat C, Brożyna AA, Janjetovic Z, et al. Melatonin and its derivatives counteract the ultraviolet B radiation-induced damage in human and porcine skin ex vivo. J Pineal Res. 2018;65(2):e12501. doi:10.1111/jpi.12501
   PubMed Web of Science ®Google Scholar
• Hao J, Fan W, Li Y, et al. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. J Exp Clin Cancer Res. 2019;38(1):48. doi:10.1186/s13046-019-1036-z
   PubMedGoogle Scholar
• London WT, Petrick J, McGlynn KA. Liver cancer. In: Cancer Epidemiology and Prevention. 4th ed. Oxford University Press; 2017:635–660.
   Google Scholar
• Lissoni P, Barni S, Cazzaniga M, et al. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone. Oncology. 1994;51(4):344–347. doi:10.1159/000227362
   PubMed Web of Science ®Google Scholar
• Lissoni P, Meregalli S, Fossati V, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori. 1994;80(6):464–467. doi:10.1177/030089169408000611
   PubMed Web of Science ®Google Scholar
• Hermann R, Podhajsky S, Jungnickel S, Lerchl A. Potentiation of antiproliferative effects of tamoxifen and ethanol on mouse hepatoma cells by melatonin: possible involvement of mitogen-activated protein kinase and induction of apoptosis. J Pineal Res. 2002;33(1):8–13. doi:10.1034/j.1600-079x.2002.01846.x
   PubMed Web of Science ®Google Scholar
• Martín-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andrés O, González P, González-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008;45(4):532–540. doi:10.1111/j.1600-079X.2008.00641.x
   PubMed Web of Science ®Google Scholar
• Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res. 2007;43(3):305–312. doi:10.1111/j.1600-079X.2007.00478.x
   PubMed Web of Science ®Google Scholar
• Liu C, Jia Z, Zhang X, et al. Involvement of melatonin in autophagy-mediated mouse hepatoma H22 cell survival. Int Immunopharmacol. 2012;12(2):394–401. doi:10.1016/j.intimp.2011.12.012
   PubMed Web of Science ®Google Scholar
• Carbajo-Pescador S, Steinmetz C, Kashyap A, et al. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer. 2013;108(2):442–449. doi:10.1038/bjc.2012.563
   PubMed Web of Science ®Google Scholar
• Fan L, Sun G, Ma T, Zhong F, Wei W. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. J Pineal Res. 2013;55(2):174–183. doi:10.1111/jpi.12060
   PubMed Web of Science ®Google Scholar
• Carbajo-Pescador S, Ordoñez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83–91. doi:10.1038/bjc.2013.285
   PubMed Web of Science ®Google Scholar
• Prieto-Domínguez N, Ordóñez R, Fernández A, et al. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61(3):396–407. doi:10.1111/jpi.12358
   PubMed Web of Science ®Google Scholar
• Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J Pineal Res. 2017;62(3):e12398. doi:10.1111/jpi.12398
   Web of Science ®Google Scholar
• Wang TH, Hsueh C, Chen CC, et al. Melatonin inhibits the progression of hepatocellular carcinoma through microRNA let7i-3p mediated RAF1 reduction. Int J Mol Sci. 2018;19(9). doi:10.3390/ijms19092687
   Web of Science ®Google Scholar
• Zhou H, Du W, Li Y, et al. Effects of melatonin on fatty liver disease: the role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy. J Pineal Res. 2018;64(1):e12450. doi:10.1111/jpi.12450
   Web of Science ®Google Scholar
• Fernández-Palanca P, Méndez-Blanco C, Fondevila F, et al. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants (Basel). 2021;10(1):103. doi:10.3390/antiox10010103
   PubMedGoogle Scholar
• Elmahallawy EK, Mohamed Y, Abdo W, Yanai T. Melatonin and mesenchymal stem cells as a key for functional integrity for liver cancer treatment. Int J Mol Sci. 2020;21(12):4521. doi:10.3390/ijms21124521
   PubMed Web of Science ®Google Scholar
• Mi L, Kuang H. Melatonin regulates cisplatin resistance and glucose metabolism through Hippo signaling in hepatocellular carcinoma cells. Cancer Manag Res. 2020;12:1863–1874. doi:10.2147/cmar.S230466
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Francis H, et al. Melatonin and circadian rhythms in liver diseases: functional roles and potential therapies. J Pineal Res. 2020;68(3):e12639. doi:10.1111/jpi.12639
   PubMed Web of Science ®Google Scholar
• Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10. doi:10.1016/j.vaccine.2006.05.115
   Web of Science ®Google Scholar
• Saavedra KP, Brebi PM, Roa JC. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012;4(1):13. doi:10.1186/1868-7083-4-13
   PubMedGoogle Scholar
• Grin W, Grünberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest. 1998;45(1):62–65. doi:10.1159/000009926
   PubMed Web of Science ®Google Scholar
• Karasek M, Kowalski AJ, Zylinska K. Serum melatonin circadian profile in women suffering from the genital tract cancers. Neuro Endocrinol Lett. 2000;21(2):109–113.
   PubMed Web of Science ®Google Scholar
• Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J. Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuro Endocrinol Lett. 2005;26(6):653–656.
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, et al. Inhibitory effect of melatonin on 7, 12-dimethylbenz[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett. 2000;156(2):199–205. doi:10.1016/s0304-3835(00)00463-8
   PubMed Web of Science ®Google Scholar
• Chen LD, Leal BZ, Reiter RJ, et al. Melatonin’s inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations. Cancer Lett. 1995;91(2):153–159. doi:10.1016/0304-3835(95)03745-i
   PubMed Web of Science ®Google Scholar
• Pariente R, Pariente JA, Rodríguez AB, Espino J. Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. J Pineal Res. 2016;60(1):55–64. doi:10.1111/jpi.12288
   PubMed Web of Science ®Google Scholar
• Pariente R, Bejarano I, Espino J, Rodríguez AB, Pariente JA. Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics. Cancer Chemother Pharmacol. 2017;80(5):985–998. doi:10.1007/s00280-017-3441-3
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang W, Cui J. Melatonin enhances TNF-α-mediated cervical cancer HeLa cells death via suppressing CaMKII/Parkin/mitophagy axis. Cancer Cell Int. 2019;19:58. doi:10.1186/s12935-019-0777-2
   PubMed Web of Science ®Google Scholar
• Wang M, Xue Y, Shen L, et al. Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer. Redox Biol. 2019;24:101225. doi:10.1016/j.redox.2019.101225
   PubMed Web of Science ®Google Scholar
• Chen L, Liu L, Li Y, Gao J. Melatonin increases human cervical cancer HeLa cells apoptosis induced by cisplatin via inhibition of JNK/Parkin/mitophagy axis. In Vitro Cell Dev Biol Anim. 2018;54(1):1–10. doi:10.1007/s11626-017-0200-z
   PubMed Web of Science ®Google Scholar
• Zare H, Shafabakhsh R, Reiter RJ, Asemi Z. Melatonin is a potential inhibitor of ovarian cancer: molecular aspects. J Ovarian Res. 2019;12(1):26. doi:10.1186/s13048-019-0502-8
   PubMedGoogle Scholar
• Nogueira LM, Sampson JN, Chu LW, et al. Individual variations in serum melatonin levels through time: implications for epidemiologic studies. PLoS One. 2013;8(12):e83208. doi:10.1371/journal.pone.0083208
   PubMed Web of Science ®Google Scholar
• Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293–303. doi:10.1177/1534735411425484
   PubMed Web of Science ®Google Scholar
• Poole EM, Schernhammer E, Mills L, Hankinson SE, Tworoger SS. Urinary melatonin and risk of ovarian cancer. Cancer Causes Control. 2015;26(10):1501–1506. doi:10.1007/s10552-015-0640-2
   PubMed Web of Science ®Google Scholar
• Lissoni P, Ardizzoia A, Barni S, Tancini G, Muttini M. Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. Oncol Rep. 1996;3(5):947–949. doi:10.3892/or.3.5.947
   PubMed Web of Science ®Google Scholar
• Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br J Cancer. 1996;74(9):1466–1468. doi:10.1038/bjc.1996.566
   PubMed Web of Science ®Google Scholar
• Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY, Kim SH. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 2012;52(2):244–252. doi:10.1111/j.1600-079X.2011.00935.x
   PubMed Web of Science ®Google Scholar
• Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, et al. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer. 2015;15:34. doi:10.1186/s12885-015-1032-4
   PubMed Web of Science ®Google Scholar
• Ganji R, Nabiuni M, Faraji R. Development of mouse preantral follicle after in vitro culture in a medium containing melatonin. Cell J. 2015;16(4):546–553. doi:10.22074/cellj.2015.499
   PubMed Web of Science ®Google Scholar
• Unver N, McAllister F. IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev. 2018;41:10–17. doi:10.1016/j.cytogfr.2018.04.004
   PubMed Web of Science ®Google Scholar
• Chuffa LG, Alves MS, Martinez M, et al. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. Endocr Relat Cancer. 2016;23(2):65–76. doi:10.1530/erc-15-0463
   PubMed Web of Science ®Google Scholar
• Shen CJ, Chang CC, Chen YT, Lai CS, Hsu YC. Melatonin suppresses the growth of ovarian cancer cell lines (OVCAR-429 and PA-1) and potentiates the effect of G1 arrest by targeting CDKs. Int J Mol Sci. 2016;17(2):176. doi:10.3390/ijms17020176
   PubMed Web of Science ®Google Scholar
• Jang H, Lee OH, Lee Y, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J Pineal Res. 2016;60(3):336–347. doi:10.1111/jpi.12316
   PubMed Web of Science ®Google Scholar
• Zonta YR, Martinez M, Camargo IC, et al. Melatonin reduces angiogenesis in serous papillary ovarian carcinoma of ethanol-preferring rats. Int J Mol Sci. 2017;18(4):763. doi:10.3390/ijms18040763
   PubMed Web of Science ®Google Scholar
• Jang H, Na Y, Hong K, et al. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1 promoter in primordial follicles. J Pineal Res. 2017;63(3):e12432. doi:10.1111/jpi.12432
   Web of Science ®Google Scholar
• Akbarzadeh M, Movassaghpour AA, Ghanbari H, et al. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. Sci Rep. 2017;7(1):17062. doi:10.1038/s41598-017-16940-y
   PubMedGoogle Scholar
• Bu S, Wang Q, Sun J, Li X, Gu T, Lai D. Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis. Cell Death Dis. 2020;11(8):644. doi:10.1038/s41419-020-02906-y
   PubMed Web of Science ®Google Scholar
• García-Navarro A, González-Puga C, Escames G, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res. 2007;43(2):195–205. doi:10.1111/j.1600-079X.2007.00463.x
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis. In: The Molecular Basis of Cancer. 1995:76.
   Google Scholar
• Cao Y. Tumor angiogenesis and therapy. Biomed Pharmacother. 2005;59:S340–S343. doi:10.1016/S0753-3322(05)80070-8
   PubMed Web of Science ®Google Scholar
• Colombo J, Maciel JM, Ferreira LC, Da Silva RF, Zuccari DA. Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells. Oncol Lett. 2016;12(1):231–237. doi:10.3892/ol.2016.4605
   PubMed Web of Science ®Google Scholar
• Cerezo AB, Hornedo-Ortega R, Álvarez-fernández MA, Troncoso AM, García-Parrilla MC. Inhibition of VEGF-induced VEGFR-2 activation and HUVEC migration by melatonin and other bioactive indolic compounds. Nutrients. 2017;9(3):249. doi:10.3390/nu9030249
   PubMed Web of Science ®Google Scholar
• Kim M, Park HJ, Seol JW, et al. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol Med. 2013;5(9):1415–1430. doi:10.1002/emmm.201302618
   PubMed Web of Science ®Google Scholar
• Lv D, Cui PL, Yao SW, Xu YQ, Yang ZX. Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. Chin J Cancer Res. 2012;24(4):310–316. doi:10.3978/j.issn.1000-9604.2012.09.03
   PubMed Web of Science ®Google Scholar
• Fischer TW, Zmijewski MA, Wortsman J, Slominski A. Melatonin maintains mitochondrial membrane potential and attenuates activation of initiator (casp-9) and effector caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes. J Pineal Res. 2008;44(4):397–407. doi:10.1111/j.1600-079X.2007.00542.x
   PubMed Web of Science ®Google Scholar
• Sánchez-Hidalgo M, Lee M, de la Lastra CA, Guerrero JM, Packham G. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res. 2012;53(4):366–373. doi:10.1111/j.1600-079X.2012.01006.x
   PubMed Web of Science ®Google Scholar
• Mełen-Mucha G, Winczyk K, Pawlikowski M. Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res. 1998;18(5a):3615–3619.
   PubMed Web of Science ®Google Scholar
• Di Bella G, Mascia F, Gualano L, Di Bella L. Melatonin anticancer effects: review. Int J Mol Sci. 2013;14(2):2410–2430. doi:10.3390/ijms14022410
   PubMed Web of Science ®Google Scholar
• Sánchez-Sánchez AM, Martín V, García-Santos G, et al. Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells. Free Radic Res. 2011;45(11–12):1333–1341. doi:10.3109/10715762.2011.623700
   PubMed Web of Science ®Google Scholar
• Yun SM, Woo SH, Oh ST, et al. Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. Mol Cell Endocrinol. 2016;422:64–73. doi:10.1016/j.mce.2015.11.016
   PubMed Web of Science ®Google Scholar
• Jung JH, Sohn EJ, Shin EA, et al. Melatonin suppresses the expression of 45S preribosomal RNA and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells. Evid Based Complement Alternat Med. 2013;2013:879746. doi:10.1155/2013/879746
   PubMed Web of Science ®Google Scholar
• Mocchegiani E, Perissin L, Santarelli L, et al. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol. 1999;21(1):27–46. doi:10.1016/s0192-0561(98)00067-8
   PubMed Web of Science ®Google Scholar
• Hu S, Shen G, Yin S, Xu W, Hu B. Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer. Adv Ther. 2009;26(9):886–892. doi:10.1007/s12325-009-0068-8
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Carughi S, De Cata A, La Viola M, Vendemiale G. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit. 2005;11(6):Cr284–288.
   PubMed Web of Science ®Google Scholar
• Fic M, Podhorska-Okolow M, Dziegiel P, et al. Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo. 2007;21(3):513–518.
   PubMed Web of Science ®Google Scholar
• Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res. 1994;54(9):2429–2432.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Fu L, Tang Z, et al. Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. Oncotarget. 2016;7(3):2985–3001. doi:10.18632/oncotarget.6407
   PubMedGoogle Scholar
• Lissoni P, Brivio F, Fumagalli L, et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 2008;28(2b):1377–1381.
   PubMed Web of Science ®Google Scholar
• Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother Radiopharm. 2007;22(1):50–55. doi:10.1089/cbr.2006.365
   PubMed Web of Science ®Google Scholar
• Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23(1):15–19. doi:10.1111/j.1600-079x.1997.tb00329.x
   PubMed Web of Science ®Google Scholar
• Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30(2):118–128. doi:10.1016/j.cdp.2006.03.002
   PubMedGoogle Scholar
• Molis TM, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 1994;8(12):1681–1690. doi:10.1210/mend.8.12.7708056
   PubMedGoogle Scholar
• Korkmaz A, Tamura H, Manchester LC, Ogden GB, Tan D-X, Reiter RJ. Combination of melatonin and a peroxisome proliferator-activated receptor-γ agonist induces apoptosis in a breast cancer cell line. J Pineal Res. 2009;46(1):115–116. doi:10.1111/j.1600-079X.2008.00635.x
   PubMed Web of Science ®Google Scholar
• Kisková T, Ekmekcioglu C, Garajová M, et al. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Eur J Cancer Prev. 2012;21(2):163–170. doi:10.1097/CEJ.0b013e32834c9c0f
   PubMed Web of Science ®Google Scholar
• Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010;12(6):R107. doi:10.1186/bcr2794
   PubMed Web of Science ®Google Scholar
• Koşar PA, Nazıroğlu M, Övey İS, Çiğ B. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels. J Membr Biol. 2016;249(1–2):129–140. doi:10.1007/s00232-015-9855-0
   PubMed Web of Science ®Google Scholar
• Debeljuk L, Feder VM, Paulucci OA. Effects of melatonin on changes induced by castration and testosterone in sexual structures of male rats. Endocrinology. 1970;87(6):1358–1360. doi:10.1210/endo-87-6-1358
   PubMedGoogle Scholar
• Lupowitz Z, Zisapel N. Hormonal interactions in human prostate tumor LNCaP cells. J Steroid Biochem Mol Biol. 1999;68(1–2):83–88. doi:10.1016/s0960-0760(98)00164-2
   PubMed Web of Science ®Google Scholar
• Jardim-Perassi BV, Arbab AS, Ferreira LC, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One. 2014;9(1):e85311. doi:10.1371/journal.pone.0085311
   PubMed Web of Science ®Google Scholar
• Schwimmer H, Metzer A, Pilosof Y, et al. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. Chronobiol Int. 2014;31(1):144–150. doi:10.3109/07420528.2013.842925
   PubMed Web of Science ®Google Scholar
• Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2011;50(2):140–149. doi:10.1111/j.1600-079X.2010.00823.x
   PubMed Web of Science ®Google Scholar
• Ferreira SG, Peliciari-Garcia RA, Takahashi-Hyodo SA, et al. Effects of melatonin on DNA damage induced by cyclophosphamide in rats. Braz J Med Biol Res. 2013;46(3):278–286. doi:10.1590/1414-431x20122230
   PubMed Web of Science ®Google Scholar
• Dauchy RT, Dauchy EM, Hanifin JP, et al. Effects of spectral transmittance through standard laboratory cages on circadian metabolism and physiology in nude rats. J Am Assoc Lab Anim Sci. 2013;52(2):146–156.
   PubMed Web of Science ®Google Scholar
• Dauchy RT, Dauchy EM, Mao L, Belancio VP, Hill SM, Blask DE. A new apparatus and surgical technique for the dual perfusion of human tumor xenografts in situ in nude rats. Comp Med. 2012;62(2):99–108.
   PubMed Web of Science ®Google Scholar